Aging and inflammation: a complex relationship revealed
A groundbreaking study has shed light on why vaccines, including those for COVID-19 and influenza, are less effective in older adults compared to younger individuals. This research challenges our traditional understanding of aging and the immune system.
For years, scientists have attributed the reduced vaccine response in older adults to a decline in immune function with age. Many have pointed to "inflammaging," a persistent, low-grade immune activation, as a key factor in this decline. However, this new study paints a different picture.
Researchers compared the immune systems of older and younger adults and found no consistent increase in biological markers of inflammation with age. Instead, the study suggests that aging reprograms T cells, which are crucial immune cells responsible for training B cells to produce antibodies in response to viruses and vaccines.
The findings, published in Nature, suggest that inflammation may not be as central to the aging process as previously believed. "We believe inflammation is driven by factors independent of a person's age," said Claire Gustafson, an assistant investigator at the Allen Institute for Immunology and a lead author of the study.
Alan Cohen, an associate professor at Columbia University who studies aging and inflammation, supports this more nuanced view of "inflammaging." He explains that while inflammation may increase with age on average in industrialized populations, it doesn't apply to everyone or every population.
"The participants in this study were from highly industrialized areas like Palo Alto and Seattle," Cohen cautions. "These findings may not be representative of different environments."
T cell changes and their impact
To improve vaccine responses in older adults, Gustafson and her team focused on T cell changes with age. They compared younger adults (aged 25-35) with an older group (aged 55-65) over two years, collecting blood samples and monitoring immune systems before and after annual flu vaccinations. The study then expanded to include adults aged 40 and above.
Using advanced techniques like single-cell RNA sequencing, high-dimensional plasma proteomics, and spectral flow cytometry, the researchers identified distinct differences in memory T cells. These immune cells "remember" past infections and help the body respond faster to future threats.
In older adults, memory T cells shift into a state that alters their interaction with B cells, impacting their ability to produce antibodies in response to infections or vaccines. In contrast, young adults' memory T cells are adept at quickly ramping up the expected antibody response.
Interestingly, these immune changes seem to occur independently of inflammation and latent virus infections, which are often blamed for weakening the immune system with age. The study found that CMV infections in individuals under 65 did not result in faster immune aging or increased inflammatory proteins.
Cohen remains cautious about the study's conclusions, noting that the most significant immune system changes typically occur after age 65. He questions whether the study's age range was sufficient to observe these changes.
The researchers believe their findings could lead to the development of vaccines that compensate for age-related immune changes, providing better protection for older adults. Additionally, the results could inform treatments to restore immune function in old age.
This study highlights the complexity of the aging process and the need for further research to fully understand the relationship between aging, inflammation, and the immune system.
